Clinical significance of serum autoantibodies in patients with NAFLD: results from the nonalcoholic steatohepatitis clinical research network
Authors:
- Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN)NCNonalcoholic Steatohepatitis Clinical Research Network (NASH CRN)
- Raj VuppalanchiRVRaj Vuppalanchi
- 10 May 2011
- journal article
- research article
- Published by Springer Nature in Hepatology International
- Vol. 6 (1) , 379-385
Abstract
Purpose Some studies have suggested that autoantibodies might define a subcategory and phenotype of nonalcoholic fatty liver disease (NAFLD) associated with advanced histological features. We evaluated the relationship between the presence of serum autoantibodies and liver histology in a large cohort of well-characterized patients with NAFLD. Methods A total of 864 NAFLD patients participating in two prospective multicentre clinical studies underwent testing for serum autoantibodies within 24 months of a liver biopsy. Liver histology was compared between the patients with and without ANA ≥ 1:160 or ASMA ≥ 1:40 or both. Results Autoantibodies were present in 182 patients (21%). There was no difference in age, gender, race, body mass index (BMI), homeostasis model assessment of insulin resistance (HOMA-IR), or history of diabetes between the two groups. Biopsies in subjects with autoantibodies were less likely to have moderate-to-severe steatosis (i.e., >33%) compared to controls (57.1 vs. 43.0%, P value = 0.0006). Lobular inflammation (46.7 vs. 47.5%), ballooning degeneration (38.5 vs. 42.5%), and advanced fibrosis (33.2 vs. 29.3%) were not different between the two groups. Histologic evidence of ‘definite’ NASH did not differ significantly between the two groups (55.5 vs. 58.9%). After adjusting for age, gender, BMI, race, and diabetes, the presence of autoantibodies was independently associated with lower prevalence of moderate-to-severe steatosis [odds ratio (OR), 0.58; 95% confidence interval (CI), 0.41–0.82; P = 0.01]. Conclusion Autoantibodies are frequently positive in NAFLD in the absence of autoimmune hepatitis and their occurrence is not associated with more advanced histologic features.Keywords
This publication has 29 references indexed in Scilit:
- Accumulation of Natural Killer T Cells in Progressive Nonalcoholic Fatty Liver DiseaseHepatology, 2010
- Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseasesModern Rheumatology, 2009
- Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial designContemporary Clinical Trials, 2009
- Clinical Correlates of Histopathology in Pediatric Nonalcoholic SteatohepatitisGastroenterology, 2008
- Is biopsy always necessary? Toward a clinico-laboratory approach for diagnosing nonalcoholic steatohepatitis in obesityHepatology, 2008
- Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markersHepatology, 2008
- The NAFLD fibrosis scoreHepatology, 2007
- Diagnosing autoimmune hepatitis in nonalcoholic fatty liver disease: is the International Autoimmune Hepatitis Group scoring system useful?Journal of Gastroenterology, 2005
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease†Hepatology, 2005
- Cryptogenic Cirrhosis: Clinical Characterization and Risk Factors for Underlying DiseaseHepatology, 1999